Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

CNS tumors remain among the deadliest forms of cancer, resisting conventional and new
treatment approaches, with mortality rates staying practically unchanged over the past 30 …

The treatment of glioblastoma has limited clinical progress over the past decade, partly due
to the lack of effective drug delivery strategies across the blood-brain-tumor barrier …

Recent advances in maximum safe glioma resection have included the introduction of a host
of visualization techniques to complement intraoperative white-light imaging of tumors …

The blood–brain barrier represents a significant challenge for the treatment of high-grade
gliomas, and our understanding of drug transport across this critical biointerface remains …

Tumor-cell-secreted extracellular vesicles (EVs) can cross the disrupted blood-brain barrier
(BBB) into the bloodstream. However, in certain gliomas, the BBB remains intact, which …

Metastatic disease in the brain is difficult to control and predicts poor prognosis. Here, we
analyze human brain metastases and demonstrate their robust infiltration by CD8+ T cell …